Pharma 2005 predictions

RSS

According to a press release from Rx Compliance Report (subscription req'd), here are some of the top enforcment trends for pharma in the coming year:

I. Scrutiny of drug marketing by state and federal prosecutors has yet to peak. "The pressure on the industry

continues to mount. The spotlight continues, to this day, to grow brighter and

brighter," says Paul Kalb, Chair, Health Law Practice, Sidley Austin Brown &

Wood.

2. Medical device sector will face dramatically increased scrutiny. "Medical device companies will begin to face real scrutiny, like their

pharma counterparts have endured in the last few years," predicts former OIG Sr

Counsel Ted Acosta.

3. Small pharma will become a growing target.

"Small pharma companies often make better targets, even though they do not have

deep pockets," says Paul DeMuro, partner, Latham & Watkins.

4.

Off-label promotion investigations will continue unabated. "Off label issues

will continue to explode," warns Bill Sarraille, Partner, Sidley Austin Brown

& Wood.

5. Drug safety investigations will overlap with investigations into promotion. "Congressional investigations into drug safety

will branch out into illegal marketing practices that promoted the unsafe

drugs," predicts Mark Kleiman, qui tam attorney.

6. Continuing medical education will rebound in 2005. "Accredited Continuing Medical Education

will survive threats from the HHS OIG and missteps from the ACCME in 2004, and

emerge even stronger by late 2005," says John Kamp, Exec Dir, Coalition for

Healthcare Communication.

7. Pharma will increasingly voluntarily curb DTC advertising. "In the face of continuing controversy over the role of

DTC advertising, industry groups will agree to more vigorous self-regulatory

measures," says Wayne Pines, President Of Regulatory Services & Healthcare,

APCO Associates.

8. New California law will continue to stymie pharma companies. "The California law will continue to be a real challenge for

pharmaceutical companies," predicts former acting HHS Inspector General Dana

Corrigan.

Please or Register to post comments.

Blog Archive

Sponsored Introduction Continue on to (or wait seconds) ×